<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3156">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745416</url>
  </required_header>
  <id_info>
    <org_study_id>DECS/JPO-CT-400-2020</org_study_id>
    <nct_id>NCT04745416</nct_id>
  </id_info>
  <brief_title>Clinical Characteristics of Patients With Leukemia and COVID-19</brief_title>
  <official_title>Clinical Characteristics of Patients With Hematological Cancer Diagnosed and Severe Acute Respiratory Syndrome Coronavirus 2 Infection at the Hospital de Alta Especialidad de Ixtapaluca and the Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the main clinical characteristics of patients with&#xD;
      de novo acute lymphoblastic leukemia treated inside the third level hospitals converted to&#xD;
      Coronavirus disease 2019 (COVID-19) attention for the metropolitan area of Mexico City.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective, observational study in patients with diagnosis of acute lymphoblastic&#xD;
      leukemia, according to the criteria of the World Health Organization, from April 2020 to&#xD;
      December 2020. Patients was cared for in the hematology department of the Hospital Regional&#xD;
      de Alta Especialidad de Ixtapaluca or the Hospital General de México. Both hospitals have&#xD;
      been assigned as Coronavirus disease 2019 (COVID-19) hospitals, limiting the access, number&#xD;
      of outpatient visits and chemotherapy protocols.&#xD;
&#xD;
      Real-time polymerase chain reaction (RT-PCR) test for Severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2) was performed for patients with respiratory symptoms or history of&#xD;
      contact with suspected / confirmed cases of COVID-19 Upon having a positive RT-PCR test,&#xD;
      patients were transferred to a respiratory isolation unit to continue their recovery. Support&#xD;
      treatment for COVID-19 was based on local considerations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Cases with more than 5 percent of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Bone marrow has less than 5 percent blast cells, blood cell counts are within the normal range, and there are no signs or symptoms of leukemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 confirmed</measure>
    <time_frame>From the date of leukemia diagnosis to the end of the induction chemotherapy cycle 1 (each cycle is 28 days)</time_frame>
    <description>Reactive SARS-CoV-2 RT-PCR test</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Leukemia, Acute</condition>
  <condition>Covid19</condition>
  <condition>Leukemia, Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Leukemia and COVID-19</arm_group_label>
    <description>Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukemia</arm_group_label>
    <description>Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with first diagnosis of acute lymphoblastic leukemia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of acute lymphoblastic leukemia according to the criteria of&#xD;
             the World Health Organization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Incomplete medical records&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad de Ixtapaluca</name>
      <address>
        <city>Ixtapaluca</city>
        <state>State Of Mexico</state>
        <zip>56530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Christian Omar Ramos-Peñafiel, MD, PhD</investigator_full_name>
    <investigator_title>Head of the hematology hospitalization area</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

